Opportunity Information: Apply for RFA CK 14 002
Apply for RFA CK 14 002
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Clinical, Epidemiologic and Ecologic Factors Impacting the Burden and Distribution of Monkeypox in Tshuapa District, Democratic Republic of the Congo" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.084 Prevention of Disease, Disability, and Death by Infectious Diseases.
- This funding opportunity was created on Nov 21, 2013 and posted on Nov 13, 2013.
- Applicants must submit their applications by Jan 13, 2014 Application Due Date January 13, 2014 by 500 PM U.S. Eastern Time.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Applicants Kinshasa School of Public Health (KSPH), University of Kinshasa, Mont Amba, Kinshasa, Democratic Republic of the Congo
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC cooperative agreement (Funding Opportunity Number RFA CK 14 002) funded a three-year research program focused on understanding and reducing the burden of human monkeypox in Tshuapa District in the Democratic Republic of the Congo. The work was planned to begin in FY2014 and run through FY2017, with funding renewed each year only if progress during the prior 12 months was considered satisfactory. The core purpose was to generate practical, field-ready evidence about how monkeypox spreads, what ecological and behavioral conditions increase risk, and which surveillance, diagnostic, prevention, and clinical approaches can most effectively limit illness and outbreak potential. While monkeypox was the primary focus, the announcement also left room to extend methods or findings to other vaccine-preventable diseases important to the DRC when relevant.
The public health rationale behind the opportunity is that monkeypox is a smallpox-like disease that is endemic in parts of the Congo Basin and appears sporadically in other areas of western sub-Saharan Africa, but at the time of the announcement nearly all cases reported annually to the World Health Organization were coming from the DRC. Because monkeypox has epidemic potential and poses an ongoing threat to health in affected communities, the CDC emphasized the need for a stronger evidence base to improve surveillance, diagnosis, prevention, and treatment. In practical terms, the award aimed to support research that connects real-world exposure pathways (including animal and human transmission) to actionable strategies that can be deployed in at-risk settings.
The grant laid out four main scientific and operational goals. First, it sought identification of ecological factors that place people at higher risk of infection, including work to pinpoint the likely sylvatic (wild animal) host or hosts that maintain monkeypox virus in nature. Second, it prioritized determining the principal modes of transmission, both zoonotic spillover (animal-to-human) and inter-human spread, to clarify how cases arise and how outbreaks propagate within households and communities. Third, it called for the development and evaluation of new or improved methods for enhanced monkeypox surveillance, along with rapid diagnostic approaches, including assays that could function as point-of-care tools in resource-limited environments. Fourth, it aimed to identify and test interventions that improve medical outcomes and reduce the introduction and spread of monkeypox in communities at elevated risk, which could include clinical management improvements, targeted prevention measures, and community-level strategies to reduce exposure and transmission.
From an administrative standpoint, this was a discretionary funding opportunity using a cooperative agreement mechanism, meaning CDC anticipated substantial involvement and collaboration during the project rather than a hands-off grant. The activity category was health, and the CFDA number listed was 93.084 (Prevention of Disease, Disability, and Death by Infectious Diseases). The opportunity anticipated a single award, with an estimated total funding level of $1,500,000 across the project period and an annual award ceiling of $500,000 (no stated award floor). There was no cost sharing or matching requirement.
Eligibility was narrow and specifically identified: the Kinshasa School of Public Health (KSPH), University of Kinshasa, Mont Amba, Kinshasa, DRC. The opportunity was posted in November 2013, with applications due January 13, 2014 by 5:00 PM U.S. Eastern Time, and it was later archived in February 2014. For access issues related to the full announcement, the listed point of contact was the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a CDC cooperative agreement funding opportunity titled RFA CK 14 002. It supported a three-year research program focused on understanding and reducing the burden of human monkeypox in Tshuapa District in the Democratic Republic of the Congo (DRC).
Who offered the award, and what type of award is it?
The award was offered by the U.S. Centers for Disease Control and Prevention (CDC) and used a cooperative agreement mechanism. That means CDC expected substantial involvement and collaboration during the project (not a hands-off grant).
What is the main purpose of the program?
The core purpose was to generate practical, field-ready evidence about how monkeypox spreads, what ecological and behavioral conditions increase risk, and which surveillance, diagnostic, prevention, and clinical approaches can most effectively limit illness and outbreak potential.
Where was the research intended to take place?
The research program was focused on Tshuapa District in the Democratic Republic of the Congo.
What time period did the project cover?
The work was planned to begin in FY2014 and run through FY2017, covering a three-year project period.
Was funding guaranteed for all three years?
No. Funding was to be renewed each year only if progress during the prior 12 months was considered satisfactory.
Why did CDC prioritize monkeypox in this opportunity?
The public health rationale stated that monkeypox is a smallpox-like disease endemic in parts of the Congo Basin and appears sporadically elsewhere in western sub-Saharan Africa. At the time of the announcement, nearly all cases reported annually to the World Health Organization were coming from the DRC. CDC emphasized the need for a stronger evidence base because monkeypox has epidemic potential and poses an ongoing threat in affected communities.
Did the program focus only on monkeypox?
Monkeypox was the primary focus, but the announcement also allowed room to extend methods or findings to other vaccine-preventable diseases important to the DRC when relevant.
What were the main goals of the funded work?
The opportunity laid out four main scientific and operational goals:
- Identify ecological factors that increase infection risk, including efforts to pinpoint likely sylvatic (wild animal) host(s) that maintain monkeypox virus in nature.
- Determine principal modes of transmission, including zoonotic spillover (animal-to-human) and inter-human spread, to clarify how cases arise and how outbreaks propagate within households and communities.
- Develop and evaluate enhanced monkeypox surveillance methods and rapid diagnostic approaches, including assays that could function as point-of-care tools in resource-limited settings.
- Identify and test interventions that improve medical outcomes and reduce the introduction and spread of monkeypox in higher-risk communities (including clinical management improvements, targeted prevention measures, and community-level strategies).
What kinds of transmission pathways were specifically mentioned?
The description highlighted both animal-to-human transmission (zoonotic spillover) and human-to-human transmission, with an emphasis on linking real-world exposure pathways to actionable strategies suitable for at-risk settings.
What diagnostic and surveillance capabilities were emphasized?
The opportunity called for new or improved methods for enhanced monkeypox surveillance and rapid diagnostic approaches, including assays that could be used as point-of-care tools in resource-limited environments.
What types of interventions were within scope?
Interventions were described broadly as approaches to improve medical outcomes and reduce introduction and spread in communities at elevated risk. Examples mentioned included clinical management improvements, targeted prevention measures, and community-level strategies to reduce exposure and transmission.
What was the activity category and CFDA number?
The activity category was health. The CFDA number listed was 93.084, titled "Prevention of Disease, Disability, and Death by Infectious Diseases."
How much funding was available?
The opportunity anticipated a single award with an estimated total funding level of $1,500,000 across the project period and an annual award ceiling of $500,000. No award floor was stated.
How many awards were expected?
The opportunity anticipated a single award.
Was cost sharing or matching required?
No. The opportunity stated there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was narrowly defined and specifically identified as the Kinshasa School of Public Health (KSPH), University of Kinshasa, Mont Amba, Kinshasa, DRC.
When was the opportunity posted and when were applications due?
The opportunity was posted in November 2013. Applications were due January 13, 2014 by 5:00 PM U.S. Eastern Time.
What is the current status of the opportunity?
The listing was later archived in February 2014.
Who should be contacted for access issues related to the full announcement?
For access issues, the point of contact listed was the CDC Procurement and Grants Office Technical Information Management Section (TIMS) at 770-488-2700.
Browse more opportunities from the same category: Health
Next opportunity: New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (Collaborative R01)
Previous opportunity: Cyber enabled Manufacturing Systems for Direct Digital Manufacturing (CeMS DDM)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CK 14 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CK 14 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (Collaborative R01) Apply for PAR 13 391 Funding Number: PAR 13 391 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01) Apply for PAR 13 392 Funding Number: PAR 13 392 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory and Developmental Grant to Improve Health Care Quality through Health Information Technology (IT) (R21) Apply for PA 14 001 Funding Number: PA 14 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $200,000 |
| Epidemiology, Prevention, and Treatment of Influenza and Other Respiratory Infections in a Malaria Endemic Area of Malawi with High HIV Prevalence Apply for RFA IP 14 002 Funding Number: RFA IP 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Advancing Patient Safety Implementation through Safe Medication Use Research (R18) Apply for PA 14 002 Funding Number: PA 14 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Collaborative Activities to Promote Metabolomics Research (Admin Supp) Apply for PA 14 003 Funding Number: PA 14 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Health Network Development Planning Program Apply for HRSA 14 043 Funding Number: HRSA 14 043 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| ATSDRs Program to Promote Localized Efforts To Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 1403 Funding Number: CDC RFA TS14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| The Cooperative Re Engagement Controlled Trial (CoRECT) Apply for RFA PS 14 001 Funding Number: RFA PS 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,300,000 |
| Reduction of Malaria in U.S. Residents Returning from Overseas Travel to Malaria Endemic Countries Apply for RFA CK 14 004 Funding Number: RFA CK 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $800,000 |
| Service Area Competition Additional Area (SAC AA) Evergreen, AL Gualala, CA Tallahassee, FL Nashua, NH Waxahachie, Texas and Kenosha, WI Apply for HRSA 14 111 Funding Number: HRSA 14 111 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Advances in Patient Safety through Simulation Research (R18) Apply for PA 14 004 Funding Number: PA 14 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Continuum of Prevention, Care and Treatment of HIV/AIDS in Most at Risk Poupulations in Cameroon CHAMP Apply for RFA 624 14 000001 Funding Number: RFA 624 14 000001 Agency: Ghana USAID Accra Category: Health Funding Amount: $18,800,000 |
| Animal and Biological Material Resource Centers (P40) Apply for PAR 14 005 Funding Number: PAR 14 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Patient Safety Learning Laboratories Innovative Design and Development to Improve Healthcare Delivery Systems (P30) Apply for RFA HS 14 005 Funding Number: RFA HS 14 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $1,000,000 |
| National Training and Technical Assistance Cooperative Agreements (NCAs) Apply for HRSA 14 031 Funding Number: HRSA 14 031 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Secondary Data Analyses to Explore NIMH Research Domain Criteria (R03) Apply for PAR 14 008 Funding Number: PAR 14 008 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01) Apply for PAR 14 009 Funding Number: PAR 14 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics Data Coordinating Center (DCC) (U01) Apply for RFA HL 14 030 Funding Number: RFA HL 14 030 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics Clinical Centers (CC) (U01) Apply for RFA HL 14 027 Funding Number: RFA HL 14 027 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CK 14 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.